Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

NCT05263895 PHASE1 COMPLETED Results posted

The purpose of this study is to estimate the relative bioavailability of PF-07321332 in different formulations in healthy adult participants.

Details

Lead sponsor	Pfizer
Phase	PHASE1
Status	COMPLETED
Enrolment	12
Start date	Thu Mar 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon May 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Bioavailability

Interventions

• PF-07321332/ritonavir
• PF-07321332/ritonavir
• PF-07321332/ritonavir
• PF-07321332/ritonavir
• PF-07321332

Countries

United States